Immunotherapy with subcutaneous injection of immunomodulatory agent (OK-432) elicits durable response in locally advanced or relapsed cervical cancer

Alas, Quenny Michelle Dyan Apat; Lin, Cheng Tao

doi:10.4103/gmit.gmit_1_19

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD8+ T cells are more infiltrated in the low-risk group, allowing for a better patient prognosis. In cervical cancer, CD8+ T cells—the primary antitumor effector cells—can cause tumor cell death 72 , 73 . Tregs are widely considered to be a tumor immunosuppressive cell that has a significant impact on the immunological escape process and can make immunotherapy much less effective.…”

Section: Discussionmentioning

confidence: 99%

Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity

Huang,

Yi,

et al. 2024

J. Cancer

View full text Add to dashboard Cite

Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) is a common gynecologic tumor and patients with advanced and recurrent disease usually have a poor clinical outcome. Angiogenesis is involved in the biological processes of tumors and can promote tumor growth and invasion. In this paper, we created a signature for predicting prognosis based on angiogenesis-related lncRNAs (ARLs). This provides a prospective direction for enhancing the efficacy of immunotherapy in CESC patients. We screened seven OS-related ARLs by univariate and multivariate regression analyses and Lasso analysis and developed a prognostic signature at the same time. Then, we performed an internal validation in the TCGA-CESC cohort to increase the precision of the study. In addition, we performed a series of analyses based on ARLs, including immune cell infiltration, immune function, immune checkpoint, tumor mutation load, and drug sensitivity analysis. Our created signature based on ARLs can effectively predict the prognosis of CESC patients. To strengthen the prediction accuracy of the signature, we built a nomogram by combining signature and clinical features.

show abstract

Section: Discussionmentioning

confidence: 99%

Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity

Huang,

Yi,

et al. 2024

J. Cancer

View full text Add to dashboard Cite

show abstract

“…It was reported to induce many cytokines including IL-1, IL-2, interferon-A, TNF-, IL-6, IL-8, granulocyte-colony stimulating factor, granulocyte-macrophage colony-stimulating factor, IL-12, and IL-18. [ 4 5 ] The mechanism includes directly inducing tumor lysis, altering cell cycle, recruiting cytotoxic cell, stimulating immune cell proliferation, or helping recognize the tumor antigen. Macrophages and dendritic cells exposure with OK-432 produce IL-12 and IL-18, which shifted the T- and B-cells' balance to Th-1 cell dominant.…”

Section: Discussionmentioning

confidence: 99%

Immunomodulating therapy by picibanil-based imiquimod and virotherapy for advanced uterine cancer after laparoscopic surgery

Peng

Huang

Cheng

et al. 2021

Gynecol Minim Invasive Ther

View full text Add to dashboard Cite

This is a case report of a uterine cancer with the International Federation of Gynecology and Obstetrics staging 3c2 with the initial clinical presentation of postmenopausal vaginal bleeding in August 2015. Endometrium biopsy showed invasive nests of poorly differentiated grade 3 endometrioid adenocarcinoma. The patient received robotic surgery including total hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic lymph node dissection, para-aortic lymph node dissection, and washing cytology. The final pathology showed an endometrioid carcinoma with myometrium invasion up to 85% and para-aortic and pelvic lymph nodes invasion. The patient received six courses of adjuvant chemotherapy (paclitaxel and carboplatin) with concurrent chemoradiotherapy after the surgery. Later, immunotherapy with Picibanil (OK-432) and interleukin-2 (IL-2) was given, and cancer did not recur for 34 months until tumor recurrence at the liver dome and bilateral lung was noted by positron-emission tomography scan in July 2018. The patient received laparoscopic surgery for intra-abdominal tumor excision in December 2018, and the tumor found extended to the right diaphragm, liver surface, omentum, bilateral flank to pelvic peritoneum, Douglas pouch, and upper rectum. We continued the immunotherapy with OK-432, IL-2, Aldara cream (imiquimod), and later on, virotherapy (human papillomavirus vaccine). The immune risk profiles showed T–cells' proliferation and alteration of the Th1/Th2 activation after immunotherapy and virotherapy. Proctectomy with colon-anal anastomosis and cytoreduction surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) (doxorubicin and paclitaxel) was performed in January 2019. After the surgery, the patient received chemotherapy (topotecan, paclitaxel, lipodox, and carboplatin) and continued the immunotherapy. The immune risk profiles showed CD4, CD4/CD8 increase after HIPEC and immunotherapy. The patient continued the therapy until May 2020.

show abstract

Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity

Gou,

Huang,

et al. 2023

Preprint

View full text Add to dashboard Cite

Cervical squamous cell carcinoma and endocervical adenocarcinoma(CESC) is a common gynecologic tumor and patients with advanced and recurrent disease usually have a poor clinical outcome. Angiogenesis is involved in the biological processes of tumors and can promote tumor growth and invasion. In this paper, we created a signature for predicting prognosis based on angiogenesis-related lncRNAs(ARLs). This provides a prospective direction for enhancing the efficacy of immunotherapy in CESC patients. We screened seven OS-related ARLs by univariate and multivariate regression analyses and Lasso analysis and developed a prognostic signature at the same time. Then, we performed an internal validation in the TCGA-CESC cohort to increase the precision of the study. In addition, we performed a series of analyses based on ARLs, including immune cell infiltration, immune function, immune checkpoint, tumor mutation load, and drug sensitivity analysis. Our created signature based on ARLs can effectively predict the prognosis of CESC patients. To strengthen the prediction accuracy of the signature, we built a nomogram by combining signature and clinical features.

show abstract

Immunotherapy with subcutaneous injection of immunomodulatory agent (OK-432) elicits durable response in locally advanced or relapsed cervical cancer

Cited by 3 publications

References 9 publications

Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity

Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity

Immunomodulating therapy by picibanil-based imiquimod and virotherapy for advanced uterine cancer after laparoscopic surgery

Angiogenesis-related lncRNAs index: A predictor for CESC prognosis, immunotherapy efficacy, and chemosensitivity

Contact Info

Product

Resources

About